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Abstract 
Simvastatin is used in treatment of hypercholesterolemia because it regulates 
cholesterol synthesis as a result of its β-hydroxy acid acting as an inhibitor of 
3-hydroxy-methylglutaryl coenzyme A (HMG-CoA). The present communication 
deals with synthesis, characterization and development of accurate, precise and 
sensitive Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
method for simultaneous estimation of simvastatin and its synthetic impurities. 
The impurities methyl ether and β-hydroxy acid of simvastatin were synthesized 
in the laboratory and characterized by MS, NMR and FT-IR spectroscopy. The 
separation of simvastatin and its impurities was carried out on an isocratic 
JASCO RP-HPLC system using KYA TECH HIQ SIL C18 column (150 x 4.6 mm 
internal diameter, particle size 5 µm) operating at ambient temperature using 
acetonitrile:water (80:20 v/v) with 0.1% orthophosphoric acid as mobile phase. 
The method developed for HPLC analysis of three impurities along with 
simvastatin was validated using ICH Q2B (R1) guidelines and it complied with 
these guidelines. The results of analysis were found to be in the range of 
98.14% to 101.89% for all analytes with acceptable accuracy and precision. The 
method can be used for detection and quantification of synthetic impurities in 
bulk or formulations of simvastatin. 
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Introduction 
Simvastatin,  (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]-
ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate,  is an 
anti-lipidemic prodrug which on in-vivo activation to its β-hydroxy acid (BHA) acts as an 
inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase and hence 
regulates cholesterol synthesis. It is mainly used for the treatment of primary hyper-
cholesterolemia, as it effectively reduces the levels of total and low-density lipoproteins 
(LDL), triglycerides and apolipoprotein B in plasma [1]. Simvastatin is obtained by 
synthesis from lovastatin (LOVA) by replacement of 2-methylbutyryl side chain with 
2,2-dimethylbutyryl group [2]. 
Strict regulatory guidelines of the International Conference on Harmonization (ICH) have 
led to an increasing need for identification and quantification of trace impurities in drugs. 
The ICH defines impurities as any component of a pharmaceutical product which is not the 
chemical entity of active substance or excipients. Such impurities if present at levels higher 
than 0.1% need to be identified and qualified with appropriate toxicological studies. If 
impurities were expected to be very toxic then identification and qualification would be 
required even at lower concentrations [3]. 
Synthesis and characterization of impurities and clinically significant metabolites of new 
drugs utilizing optimum time and resources is one of the areas of current pharmaco-
economic and clinical interest. Adequate separation, selectivity and sensitivity of detection 
and accurate quantification are always the prime concerns of pharmaceutical analyst in 
such work.  
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A large number of impurities expected to be present in simvastatin were identified, 
quantified by several analytical techniques like HPLC-UV and LC-MS [4, 5]. Several 
methods for simultaneous estimation of simvastatin and its metabolite, BHA in biological 
fluids are published [6–10]. In the present communication, we have succeeded in 
synthesis and characterization of BHA  and methyl ether of simvastatin (MES). This 
communication emphasizes use of non-compendial reference standards for quantification 
of analytes by chromatographic methods. The previously reported methods for quanti-
fication of impurities of simvastatin are having higher run time and employ various mobile 
phase modifiers like isopropyl alcohol [4]. A HPLC-UV method for simultaneous quanti-
fication of BHA, MES and LOVA along with simvastatin (Fig. 1) has been developed with 
improved analysis time and sensitivity of quantification than the previously reported 
methods [5].  
Result and Discussion 
Various regulatory authorities like ICH, USFDA, Canadian Drug and Health Agency are 
emphasizing on the purity requirements and the identification of impurities in Active 
Pharmaceutical Ingredient’s (API’s). Qualification of the impurities is the process of 
acquiring and evaluating data that establishes biological safety of an individual impurity; 
thus, revealing the need and scope of impurity profiling of drugs in  pharmaceutical 
research [11]. 
Identification of impurities is done by variety of chromatographic and spectroscopic 
techniques, either alone or in combination with other techniques. There are different 
methods for detecting and characterizing impurities like TLC, HPLC, HPTLC and AAS [12]. 
Conventional liquid chromatography, particularly, HPLC has been exploited widely in field 
of impurity profiling; the wide range of detectors, and stationary phases along with its 
sensitivity and cost effective separations have attributed to its varied applications. 
Simvastatin is synthesized semi-synthetically from LOVA in a multistep reaction [2]. 
Simvastatin may contain various types of impurities as reported in European 
Pharmacopoeia as shown in Tab. 1 [13]. The most of simvastatin impurities are not toxic 
but considering purity and quality attributes of any drug in bulk, it is mandatory to perform 
impurity profiling of simvastatin. 
Tab. 1.  European Pharmacopoeia Limits for Impurities in Simvastatin 
Name  % limit 
Simvastatin Hydroxy Acid  0.4 % 
Epilovastatin and LOVA  1.0 % 
Any other individual impurity  0.1 % 
Total impurity other than LOVA and Epilovastatin  1.0 % 
 
In present work, three impurities of simvastatin were targeted. Synthesis and 
characterization of two impurities and analytical method development for simultaneous 
estimation of three impurities along with simvastatin was carried out.  604  S. D. Jadhav et al.: 
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The first impurity targeted was BHA which is active metabolite of simvastatin, formed by 
de-esterification of cyclic lactone in simvastatin. Simvastatin hydrolyses to BHA on 
absorption of moisture. As it is metabolite of simvastatin, it is said to be qualified and does 
not require toxicity profiling [3]. The second impurity targeted was LOVA which is starting 
material for simvastatin synthesis. The third impurity MES is a byproduct expected to be 
present due to use of methanol in one of steps of simvastatin synthesis. 
 
Fig. 2.  Mass Spectra of BHA and MES 
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Fig. 3.  FT–IR Spectra of Simvastatin, BHA and MES 606  S. D. Jadhav et al.: 
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The chromatographic methods rely heavily on reference standard to provide accurate 
data. Reference standard needs to be a highly purified compound that is well 
characterized. Reference standards are of two types USP-NF and non-compendial 
reference standards. The USP-NF reference standards are official in USP, synthesized in 
reputed synthetic laboratories and are of high purity (nearly 99.99%). Their purity and cost 
is usually very high and thus do not require initial characterization before their use. Non-
compendial reference standards are synthesized in any laboratory with reasonable efforts 
but require thorough characterization to assure its identity, strength, quality and purity so 
that they can be used in quantification of impurities [14]. Non-compendial reference 
standards are usually cheaper and can be used after thorough characterization. After 
thorough characterization we have successfully used laboratory synthesized BHA and 
MES as non-compendial reference standards for their quantification from Simvastatin 
samples by RP-HPLC. The BHA was synthesized by alkaline hydrolysis of simvastatin 
while MES has been synthesized using dimethyl sulfate for methylation of β-hydroxy group 
of lactone ring. These impurities have been characterized by spectroscopic techniques 
MS, FT-IR and NMR. The mass spectra, FT-IR spectra and NMR spectra are reported in 
Fig. 2, Fig. 3 and Fig. 4 respectively. The analysis of spectral data confirmed the synthesis 
of products with desired purity and quality. Hence, these impurities have been used as 
non-compendial reference standard in quantification of impurities of simvastatin. 
The presently reported method is found to estimate three impurities along with simvastatin 
in run time of 10 minutes. In the development of this method, the first mobile phase tried 
was 50:50 acetonitrile: water (0.1% OPA) which elutes simvastatin at retention time of 41 
min. In the next trial, 80:20 acetonitrile: water (0.1% OPA) was used as mobile phase 
which elutes simvastatin at 9 min and impurities were eluted before simvastatin at 
retention times of 5.478 (MES), 6.475 (BHA) and 7.388 (LOVA) min. This method can 
effectively estimate these impurities at concentration level of 0.1 % and less. The methods 
are validated by using ICH Q2R1 (Q2B) guidelines. Linearity has been studied by plotting 
two calibration curves, one with geometrically increasing concentrations and other with 
arithmetically increasing concentrations. The calibration curve with arithmetically 
increasing concentrations is required for quantification of analytes in sample solutions 
whereas the calibration curve with concentrations increasing in geometric progression 
serve the purpose of accessing the range over which the calibration curve could be used 
for quantification. The recovery studies of impurities were found to be in range of 98.21 to 
100.72, proving accuracy of the developed method. Intra and inter day precision studies 
proves the repeatability and reproducibility of method. The analytical responses of 
impurities were found to be linear in concentration range of 0.2–25.6 µg/mL. The limits of 
detection and quantification of impurities were found to be lower than reported limit of 
impurities in European Pharmacopoeia as shown in Tab. 1.  
The reported method is simple, precise, accurate and rapid for quantification of simvastatin 
impurities along with simvastatin in its bulk form or commercial formulations. As BHA is 
also a metabolite of simvastatin, further optimization of the method for quantification of 
BHA in biological fluids could make it useful for clinical and bioequivalence studies.  
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Experimental 
Reagents and Chemicals  
The pure drug simvastatin and LOVA were procured from Biocon Lab. Bangalore (India) 
as gift sample. All HPLC grade chemicals used were procured from S.D. Fine Chem., 
Mumbai.  Water used for analysis was glass distilled using simple glass distillation 
assembly and filtered through 0.2 µm syringe filter. The impurities, BHA and MES were 
synthesized in laboratory.  
HPLC System 
The separation of simvastatin and its impurities was carried out on an isocratic JASCO 
RP-HPLC system using KYA TECH HIQ SIL C18 column operating at ambient temperature 
(150 x 4.6 mm i.d., particle size 5 µm).The pump used in this HPLC system was PU 2080 
pump (Dual piston with gear driven pump). The 20 µL sample solutions of analytes were 
injected to chromatographic system using Rheodyne Injector. The UV detector used in this 
HPLC system was Czerny turners mount monochromator with deuterium lamp as light 
source. The chromatographic and the integrated data were recorded using Hercule 2000 
(interface) computer system. Data processing was carried out using Borwin ® Version 1.5 
software. The HPLC analysis was carried out using acetonitrile: water (80:20 v/v) with 
0.1% orthophosphoric acid (OPA) as a mobile phase at a flow rate of 1.0 mL/min in an 
isocratic elution mode. Before delivering the mobile phase in to the system, it was 
degassed using sonicater and filtered through 0.20 µm syringe filter. The detection was 
performed at 237 nm.  
Gas Chromatography-Mass Spectroscopy 
A Simadzu QP 3010 mass spectroscopy interfaced with gas chromatography via electron 
impaction source was used for mass analysis and detection. A flow rate of 1 mL/min was 
used for sample analysis using Helium as mobile phase. The electron impaction source 
temperature was maintained at 280 nm. The detector used was gas chromatographic real 
analyzer. The column used was having 300 m length with 0.2 mm internal diameter.  
NMR Spectrometer 
The NMR spectrometer used for analysis was of Brucker Company; model AVNCE-300 
MHz. The NMR spectra of BHA and MES were recorded using CDCl3 as solvent.  
Synthesis of Impurities 
BHA: In 100 mL round bottom flask, 50 mL methanol and 50 mg simvastatin were taken. 
To this, 25 mL of 2N sodium hydroxide was added. It was then allowed to reflux for 2 h on 
water bath. It was then cooled and acidified with concentrated hydrochloric acid till solution 
was acidic to methyl orange. This solution was extracted 3 times with 10 mL of HPLC 
grade chloroform. Chloroform layer was separated. It was poured in petridish for 
evaporation. Solid, BHA was separated out. Product was then recrystallized with methanol 
(top, Fig. 5) 
MES: In 50 mL round bottom flask, 1 g simvastatin and 10 mL of dichloromethane was 
taken. To this, 5 mL of 50 % sodium hydroxide was added. Solution was stirred vigorously 
for 20 min and cooled in ice-  bath. Dimethyl sulfate solution was added drop wise till   Rapid Chromatographic Quantification of Simvastatin and its Synthesized Impurities  609 
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precipitation. The precipitate was washed with dilute ammonia solution to neutralize 
excess dimethyl sulfate. Precipitate was recrystallized with methanol. (bottom, Fig. 5). 
LOVA: Pure drug procured from pharmaceutical company as gift sample was used as 
standard for LOVA which is also a synthetic impurity of simvastatin. 
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Fig. 5.   Synthesis of BHA and MES from Simvastatin 
Method Validation 
The method was validated according to ICH Q2R1 (Q2B) guidelines, [15] meant for 
validation of analytical methods to check accuracy, precision, linearity range, limit of 
detection, limit of quantitation and robustness.  
Linearity Study: Standard working solutions of 10 μg/mL of simvastatin, LOVA, MES and 
BHA of simvastatin were prepared using mobile phase as a solvent. Required volume of 
solution from standard working solution was taken to get final dilutions of required strength 
for calibration curves and volume was made up with mobile phase. The HPLC analysis of 
all aliquots was carried out and response factor for each analyte was calculated. Two 
calibration curves were developed, one with geometrically increasing impurities 
concentrations (Fig. 6) and other with arithmetically increasing simvastatin concentrations 
(Fig. 7).The analytical responses of impurities were found to be linear in concentration 
range of 0.2 μg/mL to 25.6 μg/mL whereas analytical response of simvastatin was found to 
be linear in concentration range of 50 μg/ mL to 300 μg/mL. This study was carried out for 
three consecutive days. The laboratory samples were prepared using stock solutions of 
drug and impurities covering entire range of calibration curve. Amount of simvastatin and 
impurities present in laboratory sample were calculated using calibration curve data 610  S. D. Jadhav et al.: 
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(Tab. 2) obtained by area normalization method. Results of laboratory sample assay are 
reported in Table 3. 
Tab. 2.  Linearity Study of Simvastatin, LOVA, BHA and MES 
Parameters  Simvastatin  LOVA  BHA  MES 
Regression Equation  Y = A + B*C 
Range in µg/mL  50–300  0.2–25.6  0.2–25.6  0.2–25.6 
Slope (B)  4.892 × 10
−1  2.708 × 10
−3  1.098 × 10
−3  9.964 × 10
−3 
Intercept (A)  5.435 × 10
−1  9.889 × 10
−2  5.558 × 10
−2  2.957 × 10
−2 
SE
a of Slope  1.248 × 10
−2  7.547 × 10
−5  9.647 × 10
−5  5.197 × 10
−5 
SE
a of Intercept  2.347 × 10
−2  1.457 × 10
−4  2.912 × 10
−4  0.107 × 10
−4 
Correlation coefficient (r)  0.9991  0.9993  0.9990  0.9992 
C: Concentration in µg/ml Y: Unit of Response Factor a: Standard Error 
 
Specificity: The specificity of the RP-HPLC method was determined by comparison of the 
chromatogram of mixed standards and individual analyte standard sample solutions. The 
parameters like retention time, resolution and tailing factor were calculated. Good 
correlation was found between the results of mixed standards and sample solutions.  
Tab. 3.  Results of Analysis and Recovery studies 
Analyte  Concentration 
in μg/mL 
% Concentration 
Estimated
a 
(Mean ± % R.S.D.
b) 
Amount  
Added  
in mg 
% Recovery 
Estimated
a 
(Mean ± %R.S.D.
b) 
Simvastatin  100 
  99.91 ± 0.6705  80  98.37 ± 0.7846 
  99.98 ± 1.2547  100  99.31 ± 0.3204 
100.51 ± 1.1886  120  99.37 ± 1.1101 
LOVA  12.5 
  99.59 ± 0.7455  10  99.51 ± 0.2451 
  99.45 ± 0.5277  12.5  99.12 ± 0.6289 
100.04 ± 0.3240  15  99.57 ± 0.3009 
BHA  12.5 
100.74 ± 1.5565  10  99.42 ± 1.9385 
  99.24 ± 0.7042  12.5  99.88 ± 0.6470 
  99.21 ± 1.0107  15  99.58 ± 0.8047 
MES  12.5 
100.39 ± 0.3642  10  99.59 ± 0.5019 
  99.59 ± 0.27676  12.5  99.72 ± 0.5074 
100.42 ± 0.4497  15  99.87 ± 0.8337 
a Average of Three Determinations; 
b Relative Standard Deviation. 
 
Accuracy: Recovery studies were performed by standard addition method at three levels 
i.e., 80%, 100% and 120%. Known amounts of standard simvastatin and its impurities 
were added to pre-analyzed samples and they were subjected to analysis by the proposed 
HPLC method. Results of recovery studies are shown in Tab. 3.  
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Fig. 6.   Overlain Chromatogram of Increasing Impurities Concentrations 
 
Fig. 7.  Overlain Chromatogram of Increasing Simvastatin Concentrations 612  S. D. Jadhav et al.: 
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Precision: Precision study was performed to find out intra-day and inter-day variations. The 
results of precision studies are reported in Tab. 4 and values of relative standard deviation 
less than 2% indicates high degree of precision. 
Tab. 4.  Results of Precision Studies 
Parameter  % Concentration Estimated
a (Mean ±% R.S.D.
b) 
Analyte  Simvastatin  LOVA  BHA  MES 
Repeatability 
Laboratory  
Sample Analysis  99.32±1.7341  98.54±0.9547  98.33 ±1.1558  99.04 ± 1.2422 
Intermediate Precision 
Day1  Morning  99.98±0.3854  96.04 ± 1.2422  98.36 ±0.6333  98.11 ± 0.6098 
Evening  101.11±0.6739  98.33 ± 1.1558  98.37 ±0.7874  99.60 ± 0.6613 
Day2  Morning  101.02±0.9637  97.40 ± 1.2844  97.40 ±1.2844  97.98 ± 1.342 
Evening  99.84±1.6214  97.56± 1.4750  97.64 ±1.7892  96.52 ±1.2500 
a Average of Nine Determinations; 
b Relative Standard Deviation. 
 
System Suitability Parameters: These parameters were determined on freshly prepared 
standard stock solutions of simvastatin and its impurities. These analytes were injected 
into the chromatographic system under the optimized chromatographic conditions. 
Parameters that were studied to evaluate the suitability of the system are number of 
theoretical plates, tailing factor, resolution, separation factor etc [16] and are reported in 
Table 5.  
Tab. 5.  System Suitability Parameters 
Parameter  Recommended 
 Values 
MES  BHA  LOVA  Simvastatin 
Capacity factor   > 2  2.947  3.0263  2.1894  2.0421 
Resolution   > 2    2.86   
3.54  4.57 
Retention Time in minutes   –  5.4  6.4  7.4  9.0 
Tailing factor   ≤ 2  1.2  1.2  1.26  1.21 
Theoretical plates number   > 3000  6842.81  7083.81  7642.3  9044.12 
 
Limit of detection (LOD) and limit of quantitation (LOQ); The LOD and LOQ were 
separately determined based on the calibration curve data. The standard deviation of the 
y-intercepts and slope of the regression lines were used in calculating these values using 
formulae give below.  
LOD = 3.3 ×
σ
S    LOQ = 10 ×
σ
S 
where, σ = standard deviation of the response and S = slope of the calibration curve   Rapid Chromatographic Quantification of Simvastatin and its Synthesized Impurities  613 
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The LOD for MES, BHA, LOVA and simvastatin were found to be 0.030, 0.026, 0.031 and 
0.045µg/mL respectively. The LOQ for MES, BHA, LOVA and simvastatin were found to 
be 0.094, 0.081, 0.91 and 0.135µg/mL respectively. 
Robustness:  The robustness study was carried out by making small changes in the 
optimized method parameters like ± 0.1 change in pH, ± 2% change in mobile phase 
component ratio and ± 0.1mL/min change in flow rate. These changes produced no 
significant impact on percentage recoveries of drugs. The results of the robustness study 
indicated that the developed method is robust and is unaffected by small variations in the 
chromatographic conditions. 
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